tiprankstipranks
Trending News
More News >
Mirion Technologies, Inc. (MIR)
NYSE:MIR

Mirion Technologies (MIR) AI Stock Analysis

Compare
466 Followers

Top Page

MIR

Mirion Technologies

(NYSE:MIR)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
$27.00
▲(1.16% Upside)
Mirion Technologies demonstrates strong financial performance and strategic growth through acquisitions, particularly in the nuclear power sector. However, the high valuation and neutral technical indicators suggest caution. The company's ability to sustain growth and improve operational efficiency will be crucial for future performance.
Positive Factors
Revenue Growth
The consistent revenue growth indicates strong demand for Mirion's products, particularly in the nuclear power sector, supporting long-term business expansion.
Cash Flow Management
Strong cash flow management enhances financial flexibility, allowing Mirion to invest in growth opportunities and manage debt efficiently.
Nuclear Power Market Position
Mirion's growth in the nuclear power sector underscores its competitive position and potential for continued success in a critical industry.
Negative Factors
U.S. Medical Segment Challenges
Ongoing challenges in the U.S. medical segment could hinder revenue growth and profitability, impacting Mirion's overall performance.
Low Return on Equity
Low return on equity suggests inefficiencies in using shareholder capital, which could affect investor confidence and long-term growth.
Challenges in Labs and Research End Market
Reduced demand in the labs and research market may limit growth opportunities and revenue diversification for Mirion.

Mirion Technologies (MIR) vs. SPDR S&P 500 ETF (SPY)

Mirion Technologies Business Overview & Revenue Model

Company DescriptionMirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
How the Company Makes MoneyMirion Technologies generates revenue through multiple streams, primarily from the sale of its radiation detection and monitoring products, which include both hardware and software solutions. Key revenue streams include the direct sale of instruments, ongoing maintenance contracts, and dosimetry services that provide customers with essential radiation monitoring and reporting. Additionally, the company earns revenue through partnerships with government agencies, healthcare institutions, and industrial clients that require specialized radiation safety solutions. Mirion's focus on innovation and compliance with regulatory standards further enhances its market position, leading to sustained demand and recurring revenue from established clients.

Mirion Technologies Earnings Call Summary

Earnings Call Date:Oct 28, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 17, 2026
Earnings Call Sentiment Positive
The earnings call highlights strong financial performance and growth in the nuclear power end market, alongside improvements in cost of debt and free cash flow. However, challenges in the U.S. medical segment and labs and research end market present some concerns. Overall, the positive developments in nuclear power and financial metrics outweigh the challenges faced.
Q3-2025 Updates
Positive Updates
Strong Third Quarter Results
Third quarter revenue totaled $223 million, a nearly 8% increase from last year's third quarter. Adjusted EBITDA was $52.4 million, up 14.7% versus third quarter last year.
Nuclear Power End Market Growth
Nuclear power end market organic revenue grew 9% in the quarter and 11% year-to-date. Adjusted orders increased 21% in the quarter.
Cost of Debt Improvement
Year-end 2025 expected blended cost of debt of 2.8%, reflecting a 460 basis point improvement over the past year.
Positive Free Cash Flow
Third quarter adjusted free cash flow was $18 million, contributing to $53 million of year-to-date adjusted free cash flow. Adjusted free cash flow guidance increased to between $100 million and $115 million.
Medical Segment Progress
Third quarter organic revenue from dosimetry services grew 7% with digital offerings leading. Medical segment margins expanded 120 basis points to 35.9%.
Negative Updates
Pressure in U.S. Medical Segment
Current U.S. health care environment is pressuring the U.S. RTQA business, with timing and magnitude of a rebound remaining clouded due to government shutdown headwinds.
Challenges in Labs and Research End Market
Demand from the U.S. Department of Energy has been muted since the launch of DOGE and the government shutdown. Order flow from China for laboratory instruments has slowed.
Order Decline in Medical Segment
Adjusted orders in the Medical segment declined $4.7 million, primarily due to RTQA end markets' performance.
Company Guidance
In the Mirion Technologies Third Quarter 2025 Earnings Conference Call, the company provided robust guidance, emphasizing their strong performance and optimistic outlook for the nuclear power end market. Mirion reported a third-quarter revenue of $223 million, marking an 8% increase from the previous year, with organic revenue growth at 4.7%. Adjusted EBITDA rose by 14.7% to $52.4 million, driven by both the Nuclear and Safety and Medical segments, contributing to a 140 basis point margin expansion. The company highlighted the nuclear power end market, with organic revenue growth of 9% for the quarter and 11% year-to-date. Notably, Mirion raised the low end of their adjusted free cash flow guidance for 2025 to between $100 million and $115 million, driven by strong performance, and expects a conversion of 45% to 49% of adjusted EBITDA. Moreover, they reported third-quarter adjusted orders growth of 2.4%, particularly in the nuclear power sector, with significant SMR orders and newbuild projects under the EDF strategic agreement. The company reiterated its strategic acquisitions, such as Paragon Energy Solutions and Certrec, as pivotal to enhancing its portfolio and expanding its presence in the nuclear industry.

Mirion Technologies Financial Statement Overview

Summary
Mirion Technologies is on a positive trajectory with improving revenue and profitability metrics. The balance sheet is stable, with a manageable debt level and solid equity base. Strong cash flow generation further supports the company's financial health, providing flexibility for growth and investment opportunities. Continued focus on operational efficiency and profitability enhancement will be key to sustaining this momentum.
Income Statement
72
Positive
Mirion Technologies has shown a positive trend in revenue growth, with a TTM revenue increase of 1.84% and improved profitability metrics. The gross profit margin is strong at 47.18%, and the net profit margin has turned positive at 2.94% in the TTM period, indicating a recovery from previous losses. However, the EBIT margin remains modest at 6.47%, suggesting room for operational efficiency improvements.
Balance Sheet
65
Positive
The company maintains a reasonable debt-to-equity ratio of 0.67, reflecting a balanced approach to leveraging. The return on equity is low at 1.68%, indicating limited profitability relative to shareholder equity. The equity ratio stands at 52.67%, showing a solid equity base. Overall, the balance sheet is stable but could benefit from enhanced profitability.
Cash Flow
78
Positive
Mirion Technologies has demonstrated strong cash flow performance, with a free cash flow growth rate of 8.04% in the TTM period. The operating cash flow to net income ratio is healthy at 0.46, and the free cash flow to net income ratio is robust at 0.92, indicating efficient cash generation relative to earnings. This positions the company well for future investments and debt servicing.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue902.30M860.80M800.90M717.80M668.30M0.00
Gross Profit425.70M401.80M356.50M317.20M284.20M0.00
EBITDA195.30M179.00M149.00M104.30M92.60M-2.45M
Net Income26.50M-36.10M-96.90M-276.90M-222.50M-45.26M
Balance Sheet
Total Assets3.50B2.64B2.72B2.74B3.12B1.24B
Cash, Cash Equivalents and Short-Term Investments940.00M181.10M134.10M77.80M88.90M118.40M
Total Debt1.23B719.90M721.00M849.60M860.60M1.70B
Total Liabilities1.60B1.08B1.17B1.27B1.33B1.96B
Stockholders Equity1.84B1.51B1.48B1.40B1.69B-718.70M
Cash Flow
Free Cash Flow90.20M50.30M58.10M5.20M-16.70M19.60M
Operating Cash Flow128.50M99.10M95.20M39.40M900.00K39.50M
Investing Cash Flow-113.40M-43.70M-64.70M-39.50M-2.20B-75.60M
Financing Cash Flow780.00M-3.30M22.60M-7.00M1.54B118.90M

Mirion Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price26.69
Price Trends
50DMA
25.08
Positive
100DMA
24.31
Positive
200DMA
21.52
Positive
Market Momentum
MACD
0.48
Negative
RSI
64.16
Neutral
STOCH
83.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIR, the sentiment is Positive. The current price of 26.69 is above the 20-day moving average (MA) of 24.54, above the 50-day MA of 25.08, and above the 200-day MA of 21.52, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 64.16 is Neutral, neither overbought nor oversold. The STOCH value of 83.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MIR.

Mirion Technologies Risk Analysis

Mirion Technologies disclosed 47 risk factors in its most recent earnings report. Mirion Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Mirion Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$9.55B21.8620.97%1.17%3.19%69.89%
77
Outperform
$4.03B21.1821.40%1.09%8.75%64.82%
76
Outperform
$5.36B37.7313.29%0.26%14.87%15.63%
68
Neutral
$3.72B36.4811.32%0.46%-0.96%-11.55%
66
Neutral
$6.66B229.201.58%7.81%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MIR
Mirion Technologies
27.00
10.74
66.05%
FLS
Flowserve
76.62
14.81
23.96%
KAI
Kadant
327.28
-38.07
-10.42%
MWA
Mueller Water Products
26.36
3.64
16.02%
CSW
CSW Industrials
328.94
-55.00
-14.33%

Mirion Technologies Corporate Events

Private Placements and Financing
Mirion Technologies Enters New $450M Credit Agreement
Neutral
Dec 8, 2025

On December 8, 2025, Mirion Technologies, through its subsidiaries, entered into Amendment No. 6 to its Credit Agreement, originally dated October 20, 2021. This amendment introduces a new $450 million tranche of term loans maturing in 2032, which refinances all outstanding term loans under the previous agreement. The amendment also specifies interest rates for the new loans and includes a prepayment premium condition.

The most recent analyst rating on (MIR) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Mirion Technologies stock, see the MIR Stock Forecast page.

M&A Transactions
Mirion Technologies Completes Acquisition of WCI-Gigawatt
Positive
Dec 1, 2025

On December 1, 2025, Mirion Technologies, Inc. completed its acquisition of WCI-Gigawatt Intermediate Holdco, LLC, the indirect parent of Paragon Energy Solutions, LLC. This acquisition is expected to enhance Mirion’s capabilities and market positioning within the energy solutions sector.

The most recent analyst rating on (MIR) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Mirion Technologies stock, see the MIR Stock Forecast page.

Private Placements and Financing
Mirion Technologies Announces $450 Million Refinancing Plan
Neutral
Nov 7, 2025

On November 6, 2025, Mirion Technologies announced a refinancing plan involving a $450 million tranche of term loans set to mature in 2032. This move is aimed at refinancing all outstanding term loans under their existing credit agreement, with the transaction expected to close in the fourth quarter of 2025, subject to conditions.

The most recent analyst rating on (MIR) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Mirion Technologies stock, see the MIR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 07, 2025